The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

Completed · Phase 1

Conditions studied: Subjects With Varying Degrees of Renal Insufficiency and, Subjects With Normal Renal Function

In brief

RPX7009(beta-lactamase inhibitor) is being studied in combination with carbapenem (RPX2014)to treat bacterial infections, including those due to multi-drug resistant bacteria.

Key facts

Study ID

NCT02020434

Run by

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

People needed

32

Starts

2014-01-01

Expected to finish

2014-10-01

Last updated by the study team

2018-03-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females aged 18 through 80 years of age
• Willing to abstain from alcohol for 48 hours prior to dosing through discharge
• Normal volunteer first matched by age (± 10 years), BMI (± 20%), and gender to the mean values of the moderate renal insufficiency group.
• Have negative test results for HBsAg, anti-HCV antibody and anti-HIV antibody.
• Voluntarily consent to participate in the study
• Sexually abstinent or agree to use two approved methods of contraception.
• Assessment of renal insufficiency for assignment to study groups will be based on measurements of eGFR calculated by the MDRD equation at the Screening Visit to determine eligibility.

You may not qualify if…

• Unstable or new medical conditions (e.g., cardiovascular, respiratory, hepatic, renal, gastrointestinal, autoimmune, endocrine, or neurological disorders)
• Hypersensitivity or idiosyncratic reaction to β-lactam antibiotics (e.g. penicillins, cephalosporins, or carbapenems)
• History of clinically significant seizures, head injury, or meningitis.
• Current evidence or history of malignancy, excluding basal cell carcinoma, in the 2 years prior to Day -1 with no evidence of recurrence.
• Females who are pregnant, lactating, or have a positive pregnancy test
• Previously received any dose of Carbavance (RPX2014/RPX7009).
• Current participation in another investigational study or participation in another investigational clinical study within 30 days prior to the Screening Visit.
• Blood donation or significant blood loss (i.e., > 500 mL) within 56 days prior to Day 1.
• Plasma or platelet donation within 14 days prior to Day -1.
• Any acute illness requiring antibiotic drug therapy within 30 days prior to Day 1 or a febrile illness within 7 days prior to Day 1.
• Vigorous exercise from 48 hours prior to Day -1 until the day of discharge from the study.
• Positive urine drug/alcohol test at the Screening Visit or Day -1
• Concurrent use of medications known to affect the elimination of serum creatinine (e.g., trimethoprim/sulfamethoxazole [Bactrim®] or cimetidine [Tagamet®]) and competitors of renal tubular secretion (e.g., probenecid) within 30 days prior to the first dose of study drug
• Abnormal and clinically significant findings on physical examination, medical history, serum chemistry, hematology, or urinalysis
• Use of any other prescription or nonprescription drugs, vitamins, grapefruit/grapefruit juice or dietary or herbal supplements within 14 days prior to Day -1.
• Oral contraceptives are permitted for birth control.
• Acetaminophen (≤ 1 g/day) and low-dose ASA (i.e., ≤ 325 mg per day) are permitted.
• Currently receives hemodialysis or peritoneal dialysis.

Where it is running

• DaVita Clinical Research — Lakewood, Colorado, United States
• DaVita Clinical Research — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.